IL-6 Blocker Succeeds in Real-World Vasculitis
(MedPage Today) -- Clinical and laboratory improvements seen with tocilizumab in refractory giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2019 Category: Primary Care Source Type: news

IL-1 Blocker Succeeds in Real-World Vasculitis
(MedPage Today) -- Clinical and laboratory improvements seen with tocilizumab in refractory giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2019 Category: Primary Care Source Type: news

Exercise Can Shrink Belly Fat, But Not When Drug Blocks IL-6 Exercise Can Shrink Belly Fat, But Not When Drug Blocks IL-6
Exercise reduced abdominal visceral fat, a risk factor for cardiometabolic disease, but not when obese patients received tocilizumab, an anti-arthritis drug that blocks IL-6 receptors, in a new study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 27, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA approves Genentech ’s prefilled autoinjector for Actemra
Roche‘s (OTC:RHHBY) Genentech said today that the FDA approved its ACTPen single-dose prefilled autoinjector for Actemra as a new formulation for adults with moderate to severe active rheumatoid arthritis and for adults with giant cell arteritis. The U.S. regulatory agency also approved the device for administration by caregivers to patients as young as two years old with active polyarticular juvenile idiopathic arthritis or active systemic juvenile idiopathic arthritis. Get the full story at our sister site, Drug Delivery Business News.   The post FDA approves Genentech’s prefilled autoinjector for Actemra ...
Source: Mass Device - November 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Genentech Source Type: news

FDA approves the ACTPen for Roche ’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved ACTPen ™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra®(tocilizumab) as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), and for adul t patients with giant cell arteritis (GCA). (Source: Roche Investor Update)
Source: Roche Investor Update - November 26, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves The ACTpen for Actemra, A Single-Dose, Prefilled Autoinjector
South San Francisco, CA -- November 26, 2018 -- Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 26, 2018 Category: Drugs & Pharmacology Source Type: news

Tocilizumab and Work/Housework Status in Biologic-Naive RA Tocilizumab and Work/Housework Status in Biologic-Naive RA
In what ways might treatment with subcutaneous tocilizumab impact activities of daily living and work productivity among patients with rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra ® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Genentech wins FDA nod for subcutaneous formulation of arthritis drug
Roche‘s (OTC:RHHBY) Genentech reported this week that the FDA approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients two years and older. The U.S. agency approved the intravenous formulation of Actemra for the same indication in 2011. Get the full story at our sister site, Drug Delivery Business News.   The post Genentech wins FDA nod for subcutaneous formulation of arthritis drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Orthopedics Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Source Type: news

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA)
South San Francisco, CA -- September 13, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 13, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2018 Category: Pharmaceuticals Source Type: news

No Increased CVD Risk With IL-6 Blocker in RA (CME/CE)
(MedPage Today) -- Concerns had been raised because of elevated lipids with tocilizumab use (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 5, 2018 Category: Cardiology Source Type: news

Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA
This report details new and worsening subcutaneous nodulosis in a case series of patients with rheumatoid arthritis treated with the monoclonal antibody tocilizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New jab to help patients at risk of going blind from common condition
Tocilizumab, a drug that targets a chemical responsible for inflammation, could help countless people with giant cell arteritis (GCA). (Source: the Mail online | Health)
Source: the Mail online | Health - July 9, 2018 Category: Consumer Health News Source Type: news